Abeytu Naturals

Abeytu Naturals

CBD/CBG Infused Propriety Formulations

Shaman Productions is the owner of the revolutionary new Abetyu´ Naturals Product Line. Cofounded by a Clinical Scientist and a Medical Doctor, Abeytu' Naturals is using safe and effective applications of Cannabidiol Isolate plus a proprietary blend of micronutrients to assist in the management of targeted chronic medical ailments.  Shaman Productions accomplishes this by targeting Immune receptors to assist in achieving functional vs dysfunctional Immune Responses as well as addressing the four types of aging, (Liver/ Kidney/ Immune/ Metabolic). 

View on Fundanna
Security Type
Crowd SAFE
Min Investment
Offering Date
June 29, 2021
Expected Close Date
December 16, 2021
Security Price

Use of Proceeds

  • Crowdfunding Intermediary Fees of 8%
  • Campaign Marketing Expenses & Related Outreach 10%
  • Working Capital Sales and Product Marketing 35%
  • Product Development 47%
  • This is not an exhaustive list but provides guidance on the company's weighted implementation of growth operations.



Maria Crisler, CEO
Over 20 years of Clinical Experience in the multidiscipline of medicine and pathology. Former owner/operator full-service radiology center, OBgyn, Family Practice, Laboratory/Drug Analysis Clinics, Medical Aesthetics Clinics.

Emma DIponio, CMO
Over 20 years of experience as a Diagnostic Radiologist Generalist with a specialty in venous disease treatments. Former owner/operator venous disease treatment clinic and medical aesthetics clinic.

Mark Schleiger, COO
With over 25 years of operations and executive national/international experience. Mark has led teams both foreign and domestic for fortune 500 companies.

Terri Bos, CMO
Over 25 years of digital and traditional marketing experience. Multiple strategic partners for manufacturing, sourcing, and distribution.

Research Reports

No reports have been submitted

Become a Reporter

Security Description

An equity crowdfunding specific version of a SAFE used by crowdfunding portal Republic. Upon conversion (if and when that happens), investors may receive special shares with limited rights that do not show up on a company’s cap table. The issuer may roll over and not convert shares at the next financing round causing investors to lose out on some upside.

Key Deal Facts

The company has four pending patent applications using their feature formulation, pertaining to Type 1 & 2 Diabetes, HSV1 & 2, Fungus and Microbials, and other Antiviral Applications.
This exciting investment opportunity will help us bridge the gap between modern medicine and effective natural remedies, and allow our investors to be part of a worldwide movement in reducing the use of prescription medications and their side effects while offering over-the-counter alternatives without major side effects. 
We believe that Plants Do It better, and we can prove it.